LONDON, Sept. 1,
2023 /PRNewswire/ -- Virax Biolabs Group Limited
("Virax" or the "Company") (Nasdaq: VRAX), an innovative
diagnostics company focused on the detection of immune responses
and diagnosis of viral diseases, announced today the
appointment of Dr. Nigel McCracken
as the Company's Chief Operating Officer ("COO"). Dr. McCracken
will succeed Mr. Cameron Shaw, who
is moving to Virax's Advisory Board, and will lead the Company's
various growth initiatives, including the Company's expected
near-term research-use-only launch of ViraxImmune™.
"We are excited to welcome Dr. McCracken to our executive team,"
commented Mr. James Foster,
Chairman of the Board and Chief Executive Officer of Virax.
"With over 10 years of experience in diagnostics and deep
experience in various operational roles, including overseeing the
optimization and rollout of products from preclinical to commercial
stage at multinational healthcare companies including Abbott
Laboratories, Nigel is well equipped to execute on our
growth initiatives for ViraxImmune™." Mr. Foster continued,
"On behalf of the executive leadership team and the board of
directors, I would like to thank Mr. Shaw for his innumerable
contributions to Virax Biolabs and his unwavering commitment to our
overall mission."
As COO, Dr. McCracken will lead Virax's research and clinical
teams as well as the execution of the Company's go-to-market
strategy for ViraxImmune™. Prior to joining Virax, Dr. McCracken
was the Chief Scientific Officer at OTC traded BerGenBio
AsA where he drove the plan for BerGenBio AsA's companion
diagnostics and assay development. Prior to that role, he served as
COO at Nasdaq listed NuCana PLC, a clinical-stage biopharmaceutical
company focused on significantly improving treatment outcomes for
patients with cancer, where he provided oversight and direction to
the operations of the business, research and development, and
execution of corporate strategy. Dr. McCracken obtained a Master's
degree in Clinical Pharmacology from Kings
College London, a Doctor of Philosophy degree in Biochemical
Toxicology from the University of Newcastle Upon Tyne, and a Bachelor of Science
degree in Biochemistry and Pharmacology from Strathclyde University.
"Virax's immune response detection capabilities are at the
cutting edge of diagnostic innovation, and I am thrilled to be in a
position to strategically accelerate the Company's growth and build
a world class commercial organization dedicated to delivering
impactful diagnostic tools in these areas of significant need. I
look forward to working with the team to deliver on the full
promise of Virax's portfolio," commented Dr. McCracken.
In addition, Mark Ternouth,
Virax's current Chief Technology Officer, will be joining the
company's Board of Directors. Mr. Ternouth brings decades of
experience with companies such as KPMG, PricewaterhouseCoopers
(PwC), COLT Telecom, John Lewis Partnership and the United Kingdom's Home Office and Ministry of
Justice.
About Virax Biolabs Group Limited.
Founded in 2013, Virax Biolabs Group Limited is an innovative
biotech company focused on the detection of immune responses to and
diagnosis of viral diseases. In addition to distributing an array
of in-vitro diagnostic test kits, Virax Biolabs Group Limited is
currently developing a proprietary T-Cell Test technology with the
intention of providing an immunology profiling platform that
assesses each individual's immune risk profile against major global
viral threats. T-Cell testing can be particularly effective in the
diagnosis and therapeutics of COVID-19 as well as other threats
including Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus.
For more information, please
visit www.viraxbiolabs.com.
Caution Concerning Forward Looking Statements:
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. These forward-looking
statements are based on information currently available to Virax
and its current plans or expectations and are subject to a number
of known and unknown uncertainties, risks and other important
factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These and other important factors are
described in detail in the "Risk Factors" section of Virax's Annual
Report on Form 20-F for the year ended March 31, 2023.
Although we believe the expectations reflected in such
forward-looking statements are reasonable, we can give no assurance
that such expectations will prove to be correct. We are not
obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions,
the forward-looking events discussed in this press release and
other statements made from time to time by us or our
representatives might not occur.
Company Contact:
Virax Biolabs Group Limited
Phone: +44 020 7788 7414
Email: info@viraxbiolabs.com
Media and Investor Contact:
Nic Johnson and Adanna Alexander
Russo Partners, LLC
(303) 482-6405
nic.johnson@russopartnersllc.com
adanna.alexander@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-group-appoints-dr-nigel-mccracken-as-chief-operating-officer-to-oversee-growth-momentum-301915423.html
SOURCE Virax Biolabs